Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Ferrari NV — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Ferrari NV trades at $382.14 (market cap $68.73B). The key difference: Ferrari NV is far larger — about 8.1× Hinge Health Inc. Class A Common Stock's market cap, and Ferrari NV pays a 1.08% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Ferrari NV for 126 Days on average.
| HNGE | RACE | |
|---|---|---|
Market Cap | $8.48B | $68.73B |
Volume | 879,799 | 283,474 |
Sector | Health | Consumer Cyclical |
52-Week High | $105.14 | $436.54 |
52-Week Low | $31.17 | $314.63 |
Typical Hold Time | 0 Days | 126 Days |
Enterprise Value | $8.10B | $70.60B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Ferrari (RACE) trades at $387.35, down 0.49% on the day, amid a bearish technical signal. The company demonstrates strong fundamentals with revenue growth from $7.15B in 2025 to a projected $7.4B in 2026 and a net income margin of 22.25%. Recent earnings beats and a share buyback program highlight operational strength. Analyst consensus is bullish with a $462.75 price target, though technical indicators show near-term pressure with support at $384.
The outlook remains positive given Ferrari's premium brand and consistent profitability, but high valuation multiples (P/E 37.67) and economic sensitivity pose risks. Institutional buying and bullish analyst ratings support upside potential, yet investors should monitor competitive pressures and macroeconomic headwinds that could impact luxury demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
